Eli Lilly will allocate $27 billion for the construction of four manufacturing facilities in the United States. The decision was made after Donald Trump warned about the potential introduction of tariffs on imported drugs for companies without local production.

Eli Lilly plans to invest at least $27 billion in the construction of four facilities in the United States, according to a press release from the company.

This is the largest investment in manufacturing capabilities in the history of the American pharmaceutical industry, the statement notes. The project will create over 3,000 jobs for scientists, engineers, manufacturing specialists, and lab technicians.

As stated, three facilities will produce active pharmaceutical ingredients, while the fourth will manufacture injectable medications. Construction will begin this year, and they will be brought into operation within the next five years.

Since 2020, Eli Lilly has allocated more than $50 billion to expand its production in the United States. In recent years, the company has announced several major investments: $9.8 billion for an industrial complex in Indiana, $3 billion for the modernization of a plant in Wisconsin, and $1.7 billion for the construction of a facility in North Carolina. Additionally, the company has manufacturing infrastructure in Germany and Ireland, to which it has directed $2.5 billion and $1.8 billion, respectively.

 

Source: Lilly Investors